Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282438 · ClinicalTrials.gov registry record · Phase 1
Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00282438 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 2 participants.
The verdict
NCT00282438, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Sarcoidosis is a disease believed to be due to immune cells, cells which normally protect the body, but are now attacking lungs, heart, nerves, or other organs or systems within the body. As a result, the affected organs or systems fail to work properly causing difficulty breathing; heart failure; inability of the nerves to respond properly causing numbing, tingling, pain, and progressive muscle weakness; or other symptoms depending on the organ or body system involved. The likelihood of progression of this disease is high. This study is designed to examine whether treating patients with high dose cyclophosphamide (a drug which reduces the function of the immune system) and ATG (a protein that kills the immune cells that are thought to be causing this disease), followed by return of the previously collected blood stem cells will stop the progression of sarcoidosis. Stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood stream. The purpose of the high dose cyclophosphamide and ATG is to destroy the cells in the immune system. The purpose of the stem cell infusion is to evaluate whether this treatment will produce a normal immune system that will no longer attack the body.
Interventions
- BIOLOGICAL Autologous hematopoietic stem cell transplantation
- BIOLOGICAL Allogeneic stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2003-12 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282438
The ClinicalTrials.gov registry entry for NCT00282438 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Autologous hematopoietic stem cell transplantation is the first listed.
NCT00282438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282438 about?
NCT00282438 is a clinical study titled "Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis". Sarcoidosis is a disease believed to be due to immune cells, cells which normally protect the body, but are now attacking lungs, heart, nerves, or other organs or systems within the body. As a result, the affected organs or systems fail to work properly causing difficulty breathing; heart failure; i...
What is the current status of trial NCT00282438?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2003-12. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00282438?
The interventions under investigation include: Autologous hematopoietic stem cell transplantation (BIOLOGICAL), Allogeneic stem cell transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT00282438?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.